All In Biotech

Free tool

FAERS Monitor: Propylthiouracil

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 006188 or its brand name (Propylthiouracil, Propylthiouracil). Reports on generic versions are filed under their own applications.

Reports

2,081

Serious

1,801

87% of reports

Hospitalization

946

Death reported

181

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective198
  • off label use153
  • hyperthyroidism140
  • foetal exposure during pregnancy119
  • nausea88
  • anti-neutrophil cytoplasmic antibody positive vasculitis87
  • exposure during pregnancy85
  • maternal exposure during pregnancy76
  • hypotension71
  • agranulocytosis61
  • pyrexia61
  • fatigue59
  • vomiting57
  • product use in unapproved indication56
  • cardiac arrest55

Reports by year received

View as table
YearReports
200445
200539
200632
200747
200835
200930
201051
2011104
201260
201347
201479
201578
201675
201772
2018122
2019137
2020109
202197
2022102
2023188
2024231
2025205
202696

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anti-neutrophil cytoplasmic antibody positive vasculitisSignal87368.7299.030,432
hyperthyroidismSignal14098.784.013,322
agranulocytosisSignal6133.326.01,873
foetal exposure during pregnancySignal11914.812.41,523
exposure during pregnancySignal8513.811.21,001
maternal exposure during pregnancySignal768.66.9506
cardiac arrestSignal556.75.2264
hypotensionSignal713.62.8131
product use in unapproved indicationSignal562.31.840
pyrexia611.81.420
off label use1531.81.552
drug ineffective1981.51.337
vomiting571.20.92
nausea881.10.91
fatigue590.80.64

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.